ADAMTS2
Summary: This gene encodes a member of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) protein family. Members of the family share several distinct protein modules, including a propeptide region, a metalloproteinase domain, a disintegrin-like domain, and a thrombospondin type 1 (TS) motif. Individual members of this family differ in the number of C-terminal TS motifs, and some have unique C-terminal domains. The encoded preproprotein is proteolytically processed to generate the mature procollagen N-proteinase. This proteinase excises the N-propeptide of the fibrillar procollagens types I-III and type V. Mutations in this gene cause Ehlers-Danlos syndrome type VIIC, a recessively inherited connective-tissue disorder. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Feb 2016].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| ADAM metallopeptidase with thrombospondin type 1 motif 2 | MIM:604539 | Ensembl:ENSG00000087116 | HGNC:HGNC:218 | PA24546 | 5q35.3 |
GO terms in ADAMTS2
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| BP | IEA | GO:0007283 | spermatogenesis |
| BP | IEA | GO:0016485 | protein processing |
| BP | IEA | GO:0030199 | collagen fibril organization |
| BP | IEA | GO:0030324 | lung development |
| BP | IEA | GO:0030574 | collagen catabolic process |
| BP | IEA | GO:0043588 | skin development |
| CC | TAS | GO:0005576 | extracellular region |
| CC | IEA | GO:0062023 | collagen-containing extracellular matrix |
| MF | TAS | GO:0004222 | metalloendopeptidase activity |
| MF | TAS | GO:0008237 | metallopeptidase activity |
| MF | IEA | GO:0008270 | zinc ion binding |
Gene expression in normal tissue: ADAMTS2
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in ADAMTS2
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-1474244 | Extracellular matrix organization |
| reactome | R-HSA-1474290 | Collagen formation |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-1650814 | Collagen biosynthesis and modifying enzymes |
| reactome | R-HSA-3781865 | Diseases of glycosylation |
| reactome | R-HSA-3906995 | Diseases associated with O-glycosylation of proteins |
| reactome | R-HSA-392499 | Metabolism of proteins |
| reactome | R-HSA-5083635 | Defective B3GALTL causes Peters-plus syndrome (PpS) |
| reactome | R-HSA-5173105 | O-linked glycosylation |
| reactome | R-HSA-5173214 | O-glycosylation of TSR domain-containing proteins |
| reactome | R-HSA-597592 | Post-translational protein modification |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD201 | SKI II | 3 |
| iGMDRD107 | Valdecoxib | 3 |
| iGMDRD446 | LY 2183240 | 1 |
| iGMDRD152 | 179324-69-7 | 2 |
| iGMDRD163 | all trans Retinoic Acid | 3 |
| iGMDRD2 | PK-11195 | 3 |
| iGMDRD316 | N9-Isopropyl-olomoucine | 1 |
| iGMDRD634 | SCHEMBL2608041 | 7 |
| iGMDRD554 | CHEMBL1434137 | 4 |
| iGMDRD126 | Tipifarnib | 3 |
| iGMDRD579 | PF750 | 5 |
| iGMDRD772 | BRD4770 | 3 |
| iGMDRD420 | Leucascandrolide A | 5 |
| iGMDRD866 | BRD1812 | 3 |
| iGMDRD599 | Salermide | 1 |
| iGMDRD546 | BMS-754807 | 2 |
| iGMDRD427 | ABT737 | 5 |
| iGMDRD670 | ML 210 | 2 |
| iGMDRD494 | Neopeltolide | 3 |
| iGMDRD398 | Sepantronium | 2 |
| iGMDRD562 | Navitoclax | 6 |
| iGMDRD888 | Compound 44 | 3 |
| iGMDRD577 | BIX01294 | 2 |
| iGMDRD369 | TGX-115 | 3 |
| iGMDRD690 | PRIMA-1MET | 3 |
| iGMDRD356 | PNU-74654 | 3 |
| iGMDRD268 | Cerulenin | 3 |
| iGMDRD23 | Gossypol | 5 |
| iGMDRD474 | Avrainvillamide | 2 |
| iGMDRD782 | DC-45-A2 | 7 |
| iGMDRD207 | Capsaicin | 4 |
| iGMDRD52 | Rotenone | 2 |
| iGMDRD441 | TW 37 | 4 |
| iGMDRD318 | PAC-1 | 2 |
| iGMDRD85 | Ursolic acid | 5 |
| iGMDRD351 | GW843682X | 1 |
| iGMDRD314 | Tanespimycin | 2 |
| iGMDRD211 | (1S,3R)-RSL3 | 3 |
| iGMDRD132 | (-)-gallocatechin-3-O-gallate | 1 |
| iGMDRD511 | CHEMBL399379 | 2 |
| iGMDRD330 | BRD4132 | 3 |
| iGMDRD307 | Manumycin A | 2 |
| iGMDRD148 | Pifithrin-mu | 3 |
| iGMDRD299 | ICL 670 | 2 |
| iGMDRD532 | Olaparib | 1 |
| iGMDRD116 | CD437 | 1 |
| iGMDRD560 | MK-2206 | 2 |
| iGMDRD286 | Nsc 632839 | 3 |
| iGMDRD414 | MST-312 | 1 |
| iGMDRD269 | Purmorphamine | 3 |
| iGMDRD552 | AZD-1775 | 2 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD82 | Quiflapon | 4 |
| iGMDRD251 | ML162 | 2 |
| iGMDRD271 | Brefeldin A | 1 |
| iGMDRD137 | Indisulam | 5 |
| iGMDRD103 | SN-38 | 1 |
| iGMDRD5 | Tyrphostin AG 1478 | 4 |
| iGMDRD6 | AM-580 | 3 |
| iGMDRD221 | Tamoxifen | 5 |
| iGMDRD267 | Oligomycin A | 1 |
| iGMDRD213 | SMR000068650 | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in ADAMTS2
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.